← Volver a la portada
Asia · Mercados regionales · CNBC-TV18

AstraZeneca Pharma India signs LoI with Reliance's Strand Life Sciences for healthcare tie-up

Publicado por CNBC-TV18 · India hace 57 min
AstraZeneca Pharma India signs LoI with Reliance's Strand Life Sciences for healthcare tie-up - CNBC TV18
AstraZeneca Pharma India signs LoI with Reliance's Strand Life Sciences for healthcare tie-up - CNBC TV18 · CNBC-TV18

Resumen detallado

AstraZeneca Pharma India has signed a letter of intent with Reliance Industries subsidiary Strand Life Sciences to explore healthcare collaboration opportunities in India, sending its shares higher.

AstraZeneca Pharma India Ltd has signed a letter of intent (LoI) with Strand Life Sciences Private Ltd, a genomics research and diagnostics company and a subsidiary of Reliance Industries, to explore opportunities for collaboration in healthcare in India.

In a regulatory filing on Tuesday, November 17, the pharmaceutical company said the agreement would allow both sides to explore potential areas of collaboration in the Indian healthcare sector. The announcement, however, does not specify the nature or scope of the proposed partnership.

AstraZeneca Pharma India clarified that Strand Life Sciences is not a related party and that the execution of the LoI does not constitute a related-party transaction.

Following the announcement, shares of AstraZeneca Pharma India were trading 2.4% higher at ₹6,175.5 on the BSE, up ₹142.75, as of 2:43 pm.

The development comes days after the pharmaceutical company reported a 14.9% year-on-year increase in net profit to ₹62.3 crore for the second quarter of FY27, compared with ₹54.2 crore in the corresponding period last year.

Revenue from operations rose 30.4% to ₹729 crore from ₹559 crore in the year-ago quarter. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 26.7% to ₹95 crore from ₹75 crore. However, the EBITDA margin moderated to 13.1% from 13.4% a year earlier.

Also Read: AstraZeneca Pharma Q2 Results: Net profit up 15% on growth across key therapy areas

The company attributed its revenue growth to consistent performance across its oncology, biopharmaceuticals and rare disease therapy areas.

For the first half of FY27, revenue from operations stood at ₹1,411.9 crore, registering growth of around 30% over the corresponding period of the previous financial year.

Inicio del artículo, extracto de CNBC-TV18. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en CNBC-TV18 Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbctv18.com)

También te puede interesar